Adaptive Phage Therapeutics, Inc., (APT) a clinical-stage biotechnology company advancing the APT phage bank, the world’s largest therapeutic phage initiative for treatment of bacterial infectious diseases, today announced the first patient has been dosed in the PHAGE clinical trial, evaluating bacteriophage therapy in adults with cystic fibrosis (CF) who carry Pseudomonas aeruginosa (P. aeruginosa) in their lungs.
The trial is evaluating whether the bacteriophage, or “phage,” therapy is safe and able to reduce the amount of bacteria in the lungs of volunteers. The trial is being conducted by the Antibacterial Resistance Leadership Group (ARLG) which consists of more than 100 leading experts, working together to combat the ongoing antibacterial resistance crisis and improve patient care. ARLG is funded by the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). The investigational phage therapeutic, WRAIR-PAM-CF1, was developed by the Walter Reed Army Institute of Research (WRAIR) and is licensed to and manufactured by APT. The trial is expected to enroll a total of 72 patients at multiple sites across the country.
“At Adaptive Phage Therapeutics, we are committed to developing innovative treatments that address the growing problem of antibiotic resistance,” said Greg Merril, CEO of Adaptive Phage Therapeutics. “We are proud to be a part of this important trial and look forward to working with the ARLG, NIAID, WRAIR, and the CF community to bring new hope to those affected by this devastating disease and secondary respiratory infection.”
Phages are viruses that can kill or neutralize specific bacteria while leaving non-target bacteria and human cells unharmed. For more than a century, researchers have considered the potential use of phages as therapeutics, theorizing that mixtures of bacteriophages might be used on their own, or in conjunction with antibiotics, to treat bacterial infections—especially those resistant to antibiotics.
P. aeruginosa, a serious and sometimes deadly bacterium frequently acquired in healthcare settings, is the most common bacterial cause of CF exacerbations. P. aeruginosa can take advantage of the tissue damage caused by CF changes in mucus to infect and colonize the lungs. Multidrug-resistant P. aeruginosa infections are becoming increasingly common, and in recent years, only a handful of new antibiotics have been approved to treat them.
The PHAGE trial is enrolling CF patients who chronically harbor P. aeruginosa in their respiratory tracts. Participants receive WRAIR-PAM-CF1 as a single IV infusion at one of three dosage levels. Researchers will gather data on safety and microbiological activity; how the phages function in the body; how the investigational therapy affects the participants’ lung function; whether the therapy works differently on P. aeruginosa from different geographical regions; and whether the therapy changes participants’ overall quality of life.
- Philippines reports increases in most infectious diseases in 2022
- Guinea Worm Disease: ‘We are heartened that eradication can be achieved soon,’ says former President Carter
- Bangladesh: Additional Nipah virus death reported in 2023
- Salmonella outbreaks linked to pet bearded dragons update
- Brazil: Norovirus linked to Florianópolis acute diarrhea epidemic
- Thailand reports increase in melioidosis in 2022
- Grizzly bears test positive for avian influenza in Montana, First documented cases
- Measles case reported in Seattle, Individual was unvaccinated
- Nigeria: Public health advisory issued over diphtheria outbreak